Relief Therapeutics Holding SA RLF.SW Stock
Relief Therapeutics Holding SA Price Chart
Relief Therapeutics Holding SA RLF.SW Financial and Trading Overview
Relief Therapeutics Holding SA stock price | 1.26 CHF |
Previous Close | 3.39 CHF |
Open | 3.36 CHF |
Bid | 3.4 CHF x 0 |
Ask | 3.58 CHF x 0 |
Day's Range | 3.36 - 3.59 CHF |
52 Week Range | 2.82 - 16.8 CHF |
Volume | 3.74K CHF |
Avg. Volume | 14.92K CHF |
Market Cap | 39.54M CHF |
Beta (5Y Monthly) | -13.803448 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.35 CHF |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
RLF.SW Valuation Measures
Enterprise Value | 23.44M CHF |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.5021443 |
Price/Book (mrq) | 0.2719079 |
Enterprise Value/Revenue | 3.854 |
Enterprise Value/EBITDA | -0.738 |
Trading Information
Relief Therapeutics Holding SA Stock Price History
Beta (5Y Monthly) | -13.803448 |
52-Week Change | -69.66% |
S&P500 52-Week Change | 20.43% |
52 Week High | 16.8 CHF |
52 Week Low | 2.82 CHF |
50-Day Moving Average | 6.07 CHF |
200-Day Moving Average | 9.67 CHF |
RLF.SW Share Statistics
Avg. Volume (3 month) | 14.92K CHF |
Avg. Daily Volume (10-Days) | 29.55K CHF |
Shares Outstanding | 11.01M |
Float | 7.53M |
Short Ratio | N/A |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:400 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -578.98% |
Gross Margin | 79.44% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -9.99% |
Return on Equity (ttm) | -31.069% |
Income Statement
Revenue (ttm) | 6.08M CHF |
Revenue Per Share (ttm) | 0.58 CHF |
Quarterly Revenue Growth (yoy) | -14.49% |
Gross Profit (ttm) | 4.83M CHF |
EBITDA | -31740000 CHF |
Net Income Avi to Common (ttm) | -50790000 CHF |
Diluted EPS (ttm) | -4.94 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.24M CHF |
Total Cash Per Share (mrq) | 1.75 CHF |
Total Debt (mrq) | 4.34M CHF |
Total Debt/Equity (mrq) | 2.99 CHF |
Current Ratio (mrq) | 2.107 |
Book Value Per Share (mrq) | 13.203 |
Cash Flow Statement
Operating Cash Flow (ttm) | -24126000 CHF |
Levered Free Cash Flow (ttm) | -19151500 CHF |
Profile of Relief Therapeutics Holding SA
Country | Switzerland |
State | N/A |
City | Geneva |
Address | Avenue de Secheron 15 |
ZIP | 1202 |
Phone | N/A |
Website | https://www.relieftherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 69 |
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.
Q&A For Relief Therapeutics Holding SA Stock
What is a current RLF.SW stock price?
Relief Therapeutics Holding SA RLF.SW stock price today per share is 1.26 CHF.
How to purchase Relief Therapeutics Holding SA stock?
You can buy RLF.SW shares on the Swiss exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Relief Therapeutics Holding SA?
The stock symbol or ticker of Relief Therapeutics Holding SA is RLF.SW.
Which industry does the Relief Therapeutics Holding SA company belong to?
The Relief Therapeutics Holding SA industry is Biotechnology.
How many shares does Relief Therapeutics Holding SA have in circulation?
The max supply of Relief Therapeutics Holding SA shares is 12.22M.
What is Relief Therapeutics Holding SA Price to Earnings Ratio (PE Ratio)?
Relief Therapeutics Holding SA PE Ratio is now.
What was Relief Therapeutics Holding SA earnings per share over the trailing 12 months (TTM)?
Relief Therapeutics Holding SA EPS is -7.35 CHF over the trailing 12 months.
Which sector does the Relief Therapeutics Holding SA company belong to?
The Relief Therapeutics Holding SA sector is Healthcare.
Relief Therapeutics Holding SA RLF.SW included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
SPI TR SSHI | 15051.28 CHF 17125.13 USD |
-0.5
|
— — | 15030.9 CHF 17101.95 USD | 15256.93 CHF 17359.12 USD | — - | — — |
- {{ link.label }} {{link}}